{"id":"W1984547199","doi":"10.1007/s00280-006-0347-x","title":"A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Celecoxib; Cyclophosphamide; Clinical endpoint; Renal cell carcinoma; Internal medicine; Progressive disease; Toxicity; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Chemotherapy; Urology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001190504,0.0001681308,0.0004419394,0.00008137197,0.00004331438,0.000003168716,0.00003485796,0.0001006158,0.0001811202],"category_scores_gemma":[0.000002138312,0.0001332789,0.0000308038,0.0001089243,0.00015222,0.00004088993,0.00001305025,0.0001568789,3.171875e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004193807,"about_ca_system_score_gemma":0.0001132547,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001722131,"about_ca_topic_score_gemma":0.00002529585,"domain_scores_codex":[0.9991187,0.00004909359,0.000251498,0.0002299387,0.0001031422,0.0002476393],"domain_scores_gemma":[0.9996061,0.000041902,0.0001270254,0.00007306669,0.00005498253,0.00009692193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3514195,0.006129577,0.369372,0.0005760871,0.0001118698,0.0001314414,0.001028292,0.000008418783,0.2336375,0.000009012689,0.003765677,0.03381064],"study_design_scores_gemma":[0.5235868,0.01009166,0.08221164,0.00004538804,0.0001203018,0.000003676656,0.00001144448,0.0000802073,0.3804689,0.00001343871,0.003173188,0.0001933419],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973547,0.001104955,0.000002914943,0.0001177344,0.0002688712,0.0009701312,0.00001740218,0.00001136168,0.0001519352],"genre_scores_gemma":[0.9985672,0.0001962355,0.00004243733,0.0006433528,0.0002797955,0.00007980837,0.0000156181,0.00002151821,0.0001540606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2871603,"threshold_uncertainty_score":0.5434957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005171539790784135,"score_gpt":0.2636782597352365,"score_spread":0.2585067199444524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}